Oncology & Cancer

Study supports minimal residual disease as end point in myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma (MM), minimal residual disease (MRD)-negative status is associated with improved survival, according to a meta-analysis published online Sept. 15 in JAMA Oncology.

Oncology & Cancer

Researchers developing GPS for rectal cancer surgery

Researchers estimate that up to 10,000 rectal cancer patients undergo unnecessary surgery, and more than 25,000 suffer from pelvic sepsis, wound infection and permanent impairments from aggressive surgery in the United States ...

Oncology & Cancer

Minimal residual disease alone not predictive in T-cell leukemia

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. This disease includes two subtypes, B-cell and T-cell leukemia, depending upon the type of white blood cell where the leukemia originates. For B-cell ...

Oncology & Cancer

Obese youths with leukemia more likely to have persistent disease

Obese youths with acute lymphoblastic leukemia (ALL) are known to have worse outcomes than their lean counterparts. To find out why, investigators at Children's Hospital Los Angeles studied patients who were obese at the ...

page 3 from 5